Singapore Gram Negative Infection Therapeutics Market Report 2023 to 2030

Singapore Gram-Negative Infection Therapeutics Market Analysis

$ 3999

The Singapore Gram-Negative Infection Therapeutics Market was valued at $17.8 Mn in 2023 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030 to $27.7 Mn by 2030. Factors driving this expansion include increasing prevalence, rising demand for effective treatments, and an aging population. Major companies in this market include Novartis, Merck, Roche, and others.

ID: IN10SGPH563 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Aryan Patel

Buy Now

Singapore Gram-Negative Infection Therapeutics Executive Summary

The Singapore Gram-Negative Infection Therapeutics Market was valued at $17.8 Mn in 2023 and is predicted to grow at a CAGR of 6.5% from 2023 to 2030 to $27.7 Mn by 2030.

Gram-negative bacteria, distinguished by a unique cell wall structure featuring an outer membrane, present considerable challenges due to their antibiotic resistance and tendency to develop drug resistance. The emergence of multidrug-resistant strains complicates treatment strategies, prompting the exploration of next-generation antibiotics and precision medicine approaches. Infection control measures, antibiotic cycling, and computer-assisted programs are under investigation to combat resistance. Common Gram-negative pathogens such as Escherichia coli and Pseudomonas aeruginosa contribute to healthcare challenges by causing various infections. Addressing these infections involves novel antibiotics, antimicrobial stewardship programs, and diagnostic advancements.

In Singapore, Klebsiella pneumoniae accounted for 10.2% of Healthcare-Associated Infections (HAI), being the primary cause of hospital-acquired pneumonia (15.0%) and bacteremia (20.3%), highlighting a significant burden and the need for effective treatments against multidrug-resistant Gram-negative bacteria. Market growth is propelled by rising prevalence, a growing need for effective treatments, and an aging population, while cost constraints, scarce anti-microbial agents, and regulatory ambiguity act as market restraints.

Singapore Gram Negative Infection Therapeutic Market Report 2023-2030

Market Dynamics

Market Growth Drivers

Rising Prevalence of Multidrug-Resistant Infections: In a recent point-prevalence study of Healthcare-Associated Infections (HAI) in Singapore, Klebsiella pneumoniae (Kp) accounted for 10.2% of cases, ranking third among Gram-negative causes after Pseudomonas aeruginosa (11.5%) and Escherichia coli (10.4%). However, Kp was the primary cause of hospital-acquired pneumonia (15.0%) and bacteremia (20.3%). Singapore's struggle with multidrug-resistant Gram-negative bacteria, with instances of strains resistant to all existing agents, drives market demand for effective treatments.

Increasing Demand for Effective Treatments: The escalating rate and prevalence of antibiotic resistance are expected to drive growth in Singapore's market for hospital-treated gram-negative infections.

Aging Population: In 2022, residents aged 65 and above made up 18.4% of Singapore's population, up from 11.1% in 2012. By 2030, 23.8% of citizens will be aged 65 and above. The number of citizens aged 80 and above increased by over 70% from 2012 to 2023, making up 3.7% of the population. Singapore's rapidly aging demographic, with many elderly individuals, heightens susceptibility to infections, including those caused by gram-negative bacteria, thereby increasing demand for gram-negative infection therapeutics.

Market Restraints

Cost Constraints: The high expense of drug development and market entry results in pricey novel therapeutics, potentially restricting their accessibility in Singapore's cost-conscious market.

Scarce Anti-Microbial Agents: The limited availability of anti-microbial agents in pharmaceuticals hampers the growth rate of the market for gram-negative infection therapeutics.

Regulatory Ambiguity: The lack of a clear regulatory framework for antimicrobial resistance and gram-negative bacterial infections presents uncertainty and obstacles for pharmaceutical companies and healthcare providers, thus restraining the market.

Regulatory Landscape and Reimbursement Scenario

The reimbursement scenario in Singapore involves a structured approach, with the Ministry of Health (MOH) prioritizing cost-effectiveness when deciding to include new drugs on the Singapore Medication List (SML). Companies must demonstrate the drug's value proposition compared to existing options, which might involve improved patient outcomes, reduced hospital stays, and cost-effectiveness analyses. The MOH offers full reimbursement for highly effective drugs targeting critical MDR infections, limited reimbursement for specific hospitals or patient groups, or no reimbursement for costly drugs with uncertain long-term value propositions.

The National Health Insurance (NHI) Program, known as MediShield Life, offers essential hospitalization and surgical coverage, which can help offset the costs of treating gram-negative infections. Additionally, the government provides subsidies to help lower-income individuals and families afford healthcare services, including treatments for infectious diseases. Private insurance plans offer more comprehensive coverage for specialized treatments and medications to manage gram-negative infections.

Competitive Landscape

Key Players

Here are some of the major key players in the Singapore Gram-Negative Infection Therapeutics Market:

Merck & Co., Inc.
AstraZeneca
Roche
GlaxoSmithKline plc (GSK)
Pfizer Inc.
Sanofi-Aventis
Takeda Pharmaceutical Company Limited
Nektar Therapeutics
Baxter
Novartis

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Gram-Negative Infection Therapeutics Market Segmentation

By Drug Types

Antibiotics
Combination Therapies
Adjunctive Therapies

By Infection Types

Urinary Tract Infections (UTIs)
Pneumonia
Bloodstream Infections (Bacteraemia)
Wound/Surgical Site Infections
Gastrointestinal Infections
Meningitis
Hospital-Acquired Infections (HAIs)
Respiratory Tract Infections (RTIs)
Other Infections

By Route of Administration

Oral
Parenteral (injections, intravenous)
Topical

By Distribution Channel

Hospitals
Clinics
Ambulatory Surgical Centres
Home Healthcare
Long-term Care Facilities
Community Health Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.